Updated: Novartis to buy Regulus Therapeutics for up to $1.7B
Novartis plans to acquire Regulus Therapeutics for $7.00 per share in cash, or $800 million, the microRNA specialist said Wednesday. The biotech’s share price {$RGLS} jumped more than 135% in pre ...
Novartis plans to acquire Regulus Therapeutics for $7.00 per share in cash, or $800 million, the microRNA specialist said Wednesday.
The biotech’s share price {$RGLS} jumped more than 135% in pre ...
